Browsing Category
Pharma Industry News
4733 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Metastatic TNBC sees unexpected remission as Kazia Therapeutics’ Q4 update reveals pipeline momentum across cancer programs
Learn how Kazia Therapeutics’ rare iCR in metastatic TNBC is reshaping its breast cancer, immuno-oncology, and GBM pipeline strategy.
FDA authorizes breakthrough Epkinly regimen from AbbVie for relapsed or refractory follicular lymphoma
Discover how AbbVie’s newly approved Epkinly regimen with rituximab and lenalidomide is redefining treatment for relapsed or refractory follicular lymphoma.
How Arrowhead Pharmaceuticals’ first FDA-approved drug Redemplo could reshape treatment for familial chylomicronemia syndrome
Discover how Arrowhead Pharmaceuticals’ FDA approval for Redemplo could transform care for familial chylomicronemia syndrome.
RMTG and CELLGENIC unveil pre-loaded peptide pens — the next frontier in regenerative therapy
Find out how RMTG’s CELLGENIC is expanding into device-enabled regenerative therapy with its new peptide-pen line introduced at the Cancún global summit.
Phase 2 trial of Nasus Pharma’s NS002 needle-free epinephrine starts with initial dosing milestone
Find out how Nasus Pharma is advancing NS002, its needle-free intranasal epinephrine candidate, into Phase 2 trials and what it means for emergency allergy care.
Halozyme Therapeutics (HALO) completes $900m Elektrofi deal—what’s next for its royalty roadmap?
Halozyme finalizes $900M Elektrofi deal to strengthen its subcutaneous biologics platform. Discover how this move impacts future royalties and delivery formats.
Genentech’s giredestrant shows breakthrough survival benefit in early breast cancer: What lidERA revealed
Genentech’s giredestrant delivers historic survival benefit in early-stage breast cancer. Explore how the lidERA trial may redefine endocrine therapy.
Major oncology milestone as Organon and Henlius secure FDA approval for POHERDY, the first U.S. biosimilar to PERJETA
Find out how FDA approval of POHERDY, the first U.S. biosimilar to PERJETA, may transform HER2-positive breast cancer treatment costs and patient access.
Biotech breakthrough in PTSD? Silo Pharma and Allucent move toward FDA IND filing for SPC-15 therapy
Silo Pharma partners with Allucent to advance its planned FDA IND for intranasal PTSD therapeutic SPC-15. Find out how this collaboration could shape future mental health treatment.
Celcuity moves gedatolisib toward U.S. approval with NDA filing for HR+/HER2- advanced breast cancer patients
Discover how Celcuity’s FDA review for gedatolisib could expand treatment choices for HR+/HER2- PIK3CA wild-type advanced breast cancer patients.